PREFERENCES OF PEOPLE LIVING WITH HIV FOR INJECTABLE VERSUS ORAL ANTIRETROVIRAL THERAPY (ART): A DISCRETE CHOICE EXPERIMENT (DCE) ACROSS CHINA, US, UK, SPAIN, AND GERMANY
Author(s)
Christina Donatti, PhD1, EUGENA STAMULI, BSc, MSc2, Mickael HENRY, MSc3, Irina Kolobova, PhD4, Melanie Schroeder, BSc, MASc5, Ana Maria Rodriguez-Leboeuf, BSc, MSc, PhD6.
1ViiV Healthcare, TWICKENHAM, United Kingdom, 2IQVIA HELLAS S.A., Athens, Greece, 3ICON, Bas-Mauco, France, 4ViiV Healthcare, Apex, NC, USA, 5ViiV Healthcare, London, United Kingdom, 6IQVIA, Montreal, QC, Canada.
1ViiV Healthcare, TWICKENHAM, United Kingdom, 2IQVIA HELLAS S.A., Athens, Greece, 3ICON, Bas-Mauco, France, 4ViiV Healthcare, Apex, NC, USA, 5ViiV Healthcare, London, United Kingdom, 6IQVIA, Montreal, QC, Canada.
OBJECTIVES: With expanding ART options, we assessed preferences for oral and long‑acting injectable (LAI) ART attributes among people living with HIV across China, US/UK, and Spain/Germany.
METHODS: This DCE evaluated preferences among adults receiving ART in China and pooled cohorts (US/UK; Spain/Germany), varying by administration mode/frequency/setting, injection-related side effects (SEs), and general SE probability. Participants chose between two LAI and one oral profile; if oral was selected, a second choice-task with two LAI profiles followed. Oral attributes varied by general SE probability. Daily or weekly oral frequencies were offered in Spain/Germany and China; US/UK only weekly was offered. Respondents were recruited via online panels/provider referrals. A fractional factorial design generated 16 choice-tasks. Preferences were estimated using a random parameter logit model; relative attribute importance was calculated.
RESULTS: Across China (n=150), US/UK (n=351), and Spain/Germany (n=303), ≥72% were male; ≥50% in US/UK and Spain/Germany were men who have sex with men; 93% heterosexual in China. Administration frequency was a top driver across all regions; injection site pain was a leading driver in US/UK and Spain/Germany, while general SEs dominated in China. Respondents strongly preferred 6-month dosing intervals and mild/no injection pain (β>0; P<0.05), while 2-month intervals and severe pain were strongly dispreferred (β<0; P<0.05). Preference for injectable over oral therapy varied by region, with 95% selecting injectables in China, 62% in Spain/Germany, and 50% in US/UK. Attribute importance analyses showed administration frequency accounting for 40%, 30%, 19% of decision-making in US/UK, Spain/Germany, and China, respectively, followed by injection-site pain (27% in US/UK and Spain/Germany; 12% in China). General SEs had highest influence on preferences in China (33%) but lower influence in Spain/Germany (17%) and US/UK (5%).
CONCLUSIONS: Results highlight strong patient preferences for less frequent, better-tolerated treatments, with regional variability in relative importance of attributes, supporting importance of proactive shared decision-making.
METHODS: This DCE evaluated preferences among adults receiving ART in China and pooled cohorts (US/UK; Spain/Germany), varying by administration mode/frequency/setting, injection-related side effects (SEs), and general SE probability. Participants chose between two LAI and one oral profile; if oral was selected, a second choice-task with two LAI profiles followed. Oral attributes varied by general SE probability. Daily or weekly oral frequencies were offered in Spain/Germany and China; US/UK only weekly was offered. Respondents were recruited via online panels/provider referrals. A fractional factorial design generated 16 choice-tasks. Preferences were estimated using a random parameter logit model; relative attribute importance was calculated.
RESULTS: Across China (n=150), US/UK (n=351), and Spain/Germany (n=303), ≥72% were male; ≥50% in US/UK and Spain/Germany were men who have sex with men; 93% heterosexual in China. Administration frequency was a top driver across all regions; injection site pain was a leading driver in US/UK and Spain/Germany, while general SEs dominated in China. Respondents strongly preferred 6-month dosing intervals and mild/no injection pain (β>0; P<0.05), while 2-month intervals and severe pain were strongly dispreferred (β<0; P<0.05). Preference for injectable over oral therapy varied by region, with 95% selecting injectables in China, 62% in Spain/Germany, and 50% in US/UK. Attribute importance analyses showed administration frequency accounting for 40%, 30%, 19% of decision-making in US/UK, Spain/Germany, and China, respectively, followed by injection-site pain (27% in US/UK and Spain/Germany; 12% in China). General SEs had highest influence on preferences in China (33%) but lower influence in Spain/Germany (17%) and US/UK (5%).
CONCLUSIONS: Results highlight strong patient preferences for less frequent, better-tolerated treatments, with regional variability in relative importance of attributes, supporting importance of proactive shared decision-making.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD107
Topic
Economic Evaluation, Real World Data & Information Systems
Disease
Reproductive & Sexual Health